Factors driving oncologists' prescribing decisions for HER2-positive breast cancer patients

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast cancer and, according to the majority of oncologists surveyed by Decision Resources, the escalating overall cost of drug treatment for breast cancer has little or no impact on their treatment decisions.

The landscape for breast cancer therapies will become more dynamic as newer targeted agents and drug combinations launch over the next few years. Results of a survey of 101 oncologists and 30 medical directors and pharmacy directors of managed care organizations (MCOs), reveals that MCOs, through reimbursement and restrictions, have only a limited influence on prescribing of approved agents.

Further key findings